ACV01

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

A randomized, multi-site, adaptive, open-label clinical trial to determine whether autoimmune disease pts who receive the alternate vaccine for their COVID booster vaccine [RNA then vector-based or vice versa] have a better increase in anti-COVID-19 antibody response (Spike) compared to those who receive the same vaccine booster as their initial vaccination. Patients will be randomized to receive a booster with either an mRNA vaccine or a vector-based vaccine. 13 months total, 6 visits.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 08 May 2024. Study ID: 849441

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).